Guidance and quality standards Awaiting development
Showing 341 to 346 of 346
| Title | Type |
|---|---|
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477 | Technology appraisal guidance |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952 | Technology appraisal guidance |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments [ID6416] | Technology appraisal guidance |
| Zavegepant for treating acute migraine TSID 11998 | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040 | Technology appraisal guidance |
| Zuranolone for treating severe postnatal depression ID6431 | Technology appraisal guidance |